Richard Cathomas
First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Eur Urol Open Sci 2024; 68:68-74.
Sep 11, 2024First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Sep 11, 2024Eur Urol Open Sci 2024; 68:68-74
Fischer Stefanie, Gillessen Silke, Stalder Odile, Terbuch Angelika, Cathomas Richard, Schmid Florian, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Alex Kluth Luis, Seifert Bettina, Templeton Arnoud J, Mingrone Walter, Ufe Mark-Peter, Fischer Natalie Fischer, Beyer Jörg, Woelky Regina, Omlin Aurelius, Vogl Ursula M, Hoppe Katharina, Kamradt Jörn, Rothschild Sacha I, Rothermundt Christian
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels.
Fankhauser C, Wettstein M, Christiansen A, Rothermundt C, Cathomas R, Kaufmann E, Sigg S, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Beyer J, Hermanns T. Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels. Urol Oncol 2024; 42:455.e9-455.e13.
Sep 10, 2024Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels.
Sep 10, 2024Urol Oncol 2024; 42:455.e9-455.e13
Fankhauser Christian Daniel, Wettstein Marian S, Christiansen Ailsa J, Rothermundt Christian, Cathomas Richard, Kaufmann Ernest, Sigg Silvan, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Beyer Jörg, Hermanns Thomas
Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies.
Goede J, Baumann C, Cathomas R, Khanna N, Lambert J, Lehmann T, Mey U, Seebach J, Steiner U, Tschan-Plessl A, Stenner-Liewen F. Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies. Swiss Med Wkly 2024; 154:3559.
Sep 9, 2024Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies.
Sep 9, 2024Swiss Med Wkly 2024; 154:3559
Goede Jeroen, Baumann Christa K, Cathomas Richard, Khanna Nina, Lambert Jean-Francois, Lehmann Thomas, Mey Ulrich J M, Seebach Jörg, Steiner U C, Tschan-Plessl Astrid, Stenner-Liewen Frank
Re: Detection of Recurrence Through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Fankhauser C, Cathomas R, Gillessen S, Rothermundt C. Re: Detection of Recurrence Through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Eur Urol 2024; 86:477-478.
May 11, 2024Re: Detection of Recurrence Through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
May 11, 2024Eur Urol 2024; 86:477-478
Fankhauser Christian Daniel, Cathomas Richard, Gillessen Silke, Rothermundt Christian
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster K, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau H, Cattrini C, Messina C, Zeghondy J, Morelli C, Loriot Y, Formica V, Patrikidou A. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel) 2024; 16
Apr 11, 2024Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Apr 11, 2024Cancers (Basel) 2024; 16
Mokbel Sara, Baciarello Giuilia, Lavaud Pernelle, Omlin Aurelius, Calabrò Fabio, Cathomas Richard, Aeppli Stefanie, Parent Pauline, Giannatempo Patrizia, Koster Kira-Lee, Appel Naara, Gonnet Philippe, Angius Gesuino, Tsantoulis Petros, Arkenau Hendrick-Tobias, Cattrini Carlo, Messina Carlo, Zeghondy Jean, Morelli Cristina, Loriot Yohann, Formica Vincenzo, Patrikidou Anna
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
Aug 17, 2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Aug 17, 2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023; 153:40108.
Aug 15, 2023Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Aug 15, 2023Swiss Med Wkly 2023; 153:40108
Templeton Arnoud J, Omlin Aurelius, Berthold Dominik R, Beyer Jörg, Burger Irene A, Eberli Daniel, Engeler Daniel, Fankhauser Christian Daniel, Fischer Stefanie, Gillessen Silke, Nicolas Guillaume, Kroeze Stephanie G C, Lorch Anja, Müntener Michael, Papachristofilou Alexandros, Schäfer Niklaus G, Seiler Daniel, Stenner-Liewen Frank, Tsantoulis Petros, Vlajnic Tatjana, Zilli Thomas, Zwahlen Daniel Rudolf, Cathomas Richard
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023; 29:1887-1893.
May 15, 2023Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
May 15, 2023Clin Cancer Res 2023; 29:1887-1893
Omlin Aurelius, Cathomas Richard, von Amsberg Gunhild, Reuter Christoph, Feyerabend Susan, Loidl Wolfgang, Boegemann Martin, Lorch Anja, Heidenreich Axel, Tsaur Igor, Larcher-Senn Julian, Buck Stefan A J, Mathijssen Ron H J, Jaehde Ulrich, Gillessen Silke, Jörger Markus
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. Eur Urol Open Sci 2023; 51:26-38.
Mar 22, 2023Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Mar 22, 2023Eur Urol Open Sci 2023; 51:26-38
Menges Dominik, Piatti Michela C, Omlin Aurelius, Cathomas Richard, Benamran Daniel, Fischer Stefanie, Iselin Christophe E, Kueng Marc, Lorch Anja, Prause Lukas, Rothermundt Christian, O'Meara Stern Alix, Zihler Deborah, Lippuner Max, Braun Julia, Cerny Thomas, Puhan Milo Alan
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
Feb 20, 2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Feb 20, 2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.
Feb 8, 2023Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Feb 8, 2023J Clin Oncol 2023; 41:3608-3615
Gillessen Silke, Procopio Giuseppe, Hayoz Stefanie, Kremer Eloïse, Schwitter Michael, Caffo Orazio, Lorente David, Pedrazzini Augusto, Roubaud Guilhem, Nenan Soazig, Omlin Aurelius, Buttigliero Consuelo, Delgado Mingorance Juan Ignacio, González-Del-Alba Aránzazu, Delgado Maria Teresa, Nolè Franco, Turco Fabio, Mestre Ricardo Pereira, Ribi Karin, Cathomas Richard
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol 2022; 12:1056823.
Dec 8, 2022Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Dec 8, 2022Front Oncol 2022; 12:1056823
Christiansen Ailsa J, Lobo João, Fankhauser Christian D, Rothermundt Christian, Cathomas Richard, Batavia Aashil A, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Jörg, Hermanns Thomas
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
Nov 12, 2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Nov 12, 2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold D, Putora P, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A, Schaer C, Biaggi C, Gillessen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23:1441-1450.
Oct 10, 2022Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
Oct 10, 2022Lancet Oncol 2022; 23:1441-1450
Papachristofilou Alexandros, Bedke Jens, Hayoz Stefanie, Schratzenstaller Ulrich, Pless Miklos, Hentrich Marcus, Krege Susanne, Lorch Anja, Aebersold Daniel-M, Putora Paul Martin, Berthold Dominik-R, Zihler Deborah, Zengerling Friedemann, Dieing Annette, Mueller Arndt-Christian, Schaer Corinne, Biaggi Christine, Gillessen Silke, Cathomas Richard
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S, Seifert B, Templeton A, Terbuch A, Ufen M, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022; 40:16-18.
Apr 26, 2022Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Apr 26, 2022Eur Urol Open Sci 2022; 40:16-18
Pratsinis Manolis, Fankhauser Christian, Pratsinis Katerina, Beyer Jörg, Bührer Emanuel, Cathomas Richard, Fischer Natalie, Hermanns Thomas, Hirschi-Blickenstorfer Anita, Kamradt Jörn, Alex Kluth Luis, Zihler Deborah, Mingrone Walter, Müller Beat, Nestler Tim, Rothschild Sacha I, Seifert Bettina, Templeton Arnoud J, Terbuch Angelika, Ufen Mark-Peter, Woelky Regina, Gillessen Silke, Rothermundt Christian
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Fankhauser C, Christiansen A, Rothermundt C, Cathomas R, Wettstein M, Grossmann N, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2021; 126:1140-1144.
Dec 15, 2021Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Dec 15, 2021Br J Cancer 2021; 126:1140-1144
Fankhauser Christian D, Christiansen Ailsa J, Rothermundt Christian, Cathomas Richard, Wettstein Marian S, Grossmann Nico C, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Joerg, Hermanns Thomas
Swiss germ-cell cancer consensus recommendations
Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bührer E. Swiss germ-cell cancer consensus recommendations. Swiss Med Wkly 2021; 151
Aug 23, 2021Swiss germ-cell cancer consensus recommendations
Aug 23, 2021Swiss Med Wkly 2021; 151
Beyer Jörg, Stenner Frank, Spahn Martin, Seiler Roland, Rothermundt Christian, Roth Beat, Papachristofilou Alexandros, Omlin Aurelius, Lorch Anja, Honecker Friedemann, Hermanns Thomas, Gross Tobias, Gillessen Silke, Fischer Stefanie, Fankhauser Christian D, Cathomas Richard, Bode Peter-Karl, Berthold Dominik, Bührer Emanuel
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
Jul 12, 2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Jul 12, 2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly 2021; 151:w20464.
Mar 1, 2021Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Mar 1, 2021Swiss Med Wkly 2021; 151:w20464
Stoffel Sandro Tiziano, Lupatsch Judith E, Schwenkglenks Matthias, Dietrich Daniel, Schär Corinne, Feller Anita, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Gillessen Silke, Cathomas Richard, Thürlimann Beat, von Moos Roger, Mark Michael Thomas
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC cancer 2021; 21:182.
Feb 19, 2021Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Feb 19, 2021BMC cancer 2021; 21:182
Ribi Karin, von Moos Roger, Caspar Clemens B, Mannhart Meinrad, von Burg Philippe, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Thürlimann Beat, Mark Michael